Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OXY-APS: Enhancing Social Skills in Schizophrenia Spectrum Disorders
NCT06881810Phase 2Active, not recruiting
- Sponsor
- Central Institute of Mental Health
- Start
- Aug 2024
- Primary completion
- Mar 2028
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of oxytocin nasal spray in Schizophrenia Spectrum Disorders (SSD) (2 arms), sponsored by Central Institute of Mental Health. Primary endpoint: Personal and Social Performance Scale at 12 weeks. Started Aug 2024; status: active, not recruiting.
02
Drugs
oxytocin nasal spray
03
Conditions
Schizophrenia Spectrum Disorders (SSD)
Beyond the preview
Go deeper on NCT06881810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06881810.